Cargando…

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

BACKGROUND: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival. METHODS: Thirty-nine consecutive patients with mR...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnebo, Jacob, Grybäck, Per, Harmenberg, Ulrika, Laurell, Anna, Wersäll, Peter, Blomqvist, Lennart K, Ullén, Anders, Sandström, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064288/
https://www.ncbi.nlm.nih.gov/pubmed/24906441
http://dx.doi.org/10.1186/1471-2407-14-408
_version_ 1782321935097528320
author Farnebo, Jacob
Grybäck, Per
Harmenberg, Ulrika
Laurell, Anna
Wersäll, Peter
Blomqvist, Lennart K
Ullén, Anders
Sandström, Per
author_facet Farnebo, Jacob
Grybäck, Per
Harmenberg, Ulrika
Laurell, Anna
Wersäll, Peter
Blomqvist, Lennart K
Ullén, Anders
Sandström, Per
author_sort Farnebo, Jacob
collection PubMed
description BACKGROUND: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival. METHODS: Thirty-nine consecutive patients with mRCC were included prospectively and underwent PET examinations prior to and after 14 and 28 days of standard treatment with sunitinib (n = 18), sorafenib (n = 19) or pazopanib (n = 2). The PET response was analyzed in terms of SUVmax, SULpeak, and total lesion glycolysis and a positive response (defined as a 30% reduction) compared to overall and progression- free survival. RESULTS: Thirty-five patients with at least one metabolically active metastatic lesion prior to treatment underwent additional FDG-PET examinations after 14 (n = 32) and/or 28 days (n = 30) of treatment. Changes in either SULpeak or total lesion glycolysis were correlated to both progression-free and overall survival (for TLG2.5 responders, HR = 0.38 (95% CI: 0.18-0.83) and 0.22 (95% CI: 0.09-0.53), and for TLG50 responders, HR = 0.25 (0.10-0.62) and 0.25 (95% CI: 0.11-0.57) and for SULpeak responders, HR = 0.39 (95% CI: 0.17-0.91) and 0.38 (95% CI: 0.15-0.93), respectively). In contrast SUVmax response did not predict progression- free or overall survival (HR = 0.43 (95% CI: 0.18-1.01) and 0.50 (95% CI: 0.21-1.19), respectively). CONCLUSIONS: Assessment of early changes in SULpeak and total lesion glycolysis undergoing treatment with tyrosine kinase inhibitors by FDG-PET can possibly predict progression- free and overall survival in patients with mRCC.
format Online
Article
Text
id pubmed-4064288
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40642882014-06-21 Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma Farnebo, Jacob Grybäck, Per Harmenberg, Ulrika Laurell, Anna Wersäll, Peter Blomqvist, Lennart K Ullén, Anders Sandström, Per BMC Cancer Research Article BACKGROUND: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival. METHODS: Thirty-nine consecutive patients with mRCC were included prospectively and underwent PET examinations prior to and after 14 and 28 days of standard treatment with sunitinib (n = 18), sorafenib (n = 19) or pazopanib (n = 2). The PET response was analyzed in terms of SUVmax, SULpeak, and total lesion glycolysis and a positive response (defined as a 30% reduction) compared to overall and progression- free survival. RESULTS: Thirty-five patients with at least one metabolically active metastatic lesion prior to treatment underwent additional FDG-PET examinations after 14 (n = 32) and/or 28 days (n = 30) of treatment. Changes in either SULpeak or total lesion glycolysis were correlated to both progression-free and overall survival (for TLG2.5 responders, HR = 0.38 (95% CI: 0.18-0.83) and 0.22 (95% CI: 0.09-0.53), and for TLG50 responders, HR = 0.25 (0.10-0.62) and 0.25 (95% CI: 0.11-0.57) and for SULpeak responders, HR = 0.39 (95% CI: 0.17-0.91) and 0.38 (95% CI: 0.15-0.93), respectively). In contrast SUVmax response did not predict progression- free or overall survival (HR = 0.43 (95% CI: 0.18-1.01) and 0.50 (95% CI: 0.21-1.19), respectively). CONCLUSIONS: Assessment of early changes in SULpeak and total lesion glycolysis undergoing treatment with tyrosine kinase inhibitors by FDG-PET can possibly predict progression- free and overall survival in patients with mRCC. BioMed Central 2014-06-06 /pmc/articles/PMC4064288/ /pubmed/24906441 http://dx.doi.org/10.1186/1471-2407-14-408 Text en Copyright © 2014 Farnebo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Farnebo, Jacob
Grybäck, Per
Harmenberg, Ulrika
Laurell, Anna
Wersäll, Peter
Blomqvist, Lennart K
Ullén, Anders
Sandström, Per
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title_full Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title_fullStr Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title_full_unstemmed Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title_short Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
title_sort volumetric fdg-pet predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064288/
https://www.ncbi.nlm.nih.gov/pubmed/24906441
http://dx.doi.org/10.1186/1471-2407-14-408
work_keys_str_mv AT farnebojacob volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT grybackper volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT harmenbergulrika volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT laurellanna volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT wersallpeter volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT blomqvistlennartk volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT ullenanders volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma
AT sandstromper volumetricfdgpetpredictsoverallandprogressionfreesurvivalafter14daysoftargetedtherapyinmetastaticrenalcellcarcinoma